In 147 patients with untreated BRAF V600E-mutant metastatic colorectal cancer, encorafenib + cetuximab + FOLFIRI raised objective response vs FOLFIRI ± bevacizumab (64.4% vs 39.2%); median PFS 15.2 vs 8.3 months (HR 0.44). Serious adverse events 49.3% vs 44.1%.
RCTn = 147
Kopetz et al. A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3